Human Anti-CD7 Recombinant Antibody (clone CHT2) (CAT#: FAMAB-0049CQ)

Figure 1 Immunohistologic specificity of the binding of RFT2 (A and B) and CHT2 (C and D) on normal thymus(A and C) and tonsil (B and D).

Note the identical reactivity pattern and the simiby both mAb. Arrows point to very larly wide range of staining intensity seen strongly positive T blast cells inslde the thymic cortex. In Band D the broken line delineates the boundary between the follicle with germinal center (gc) and the T cell-rich paracortical region (PC). ascertained by double staining for IgM deposits in the germinal center (not shown). Apart from T lineage cells no other cell types In the body are labeled with CHTP.

Heinrich, G., Gram, H., Kocher, H. P., Schreier, M. H., Ryffel, B., Akbar, A., ... & Janossy, G. (1989). Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions. The Journal of Immunology, 143(11), 3589-3597.

Figure 2 Triple immunofluorescent analysis of RFTP (E and D) and CHT2, reactivity(C and E) of blood lymphocytes expressing CD45 R (LCA, p220.200: A, B, and C) and UCHLl (LCA. p180: A. D, and E).

The lymphocyte populations were gated on the forward angle and side scatterby using a FACScan flow cytometer. The three immunofluroescent channels included DuoCHROME (DC; UCHL1-biotin with streptavidin second layer) phycoerythrin (PE; directly labeled CD45R) and FITC. The latter was either used directly (RFT2-FITC) or indirectly (CHT2 with goat antihuman-Ig-FITC). The B lymphocyte populations (strongly CD45R+. but UCHLI- RFT2-) shown in boxes represent 7.0% of lymphocytes counted.

Heinrich, G., Gram, H., Kocher, H. P., Schreier, M. H., Ryffel, B., Akbar, A., ... & Janossy, G. (1989). Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions. The Journal of Immunology, 143(11), 3589-3597.

Figure 3 CD7 expression detected by RFTP (a) and CHTP (b) on T lymphoid populations.

(A) unstimulated UCHLl+ T lymphocytes; (B) unstimulated CD45R+ T cells; (C) T-ALL blast cells; (D) lymphoblasts from 64-h PHA stimulated cultures. Note that "A" include CD7- and CD7± cells, "B" include CD7+ cells, whereas both T-ALL blasts and T lymphoblasts show even stronger positivity. RFTP was conjugated to FITC and CHTPbiotin was detected with streptavidin-FITC

Heinrich, G., Gram, H., Kocher, H. P., Schreier, M. H., Ryffel, B., Akbar, A., ... & Janossy, G. (1989). Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions. The Journal of Immunology, 143(11), 3589-3597.

Figure 4 ADCC using CF⁵¹-labeled T-ALL (a and b, two cases) or PHA blasts (c).

Effector cells were PBMC from healthy donors. Target cells were coated with CHTP, RFTZ or uncoated by using a control irrelevant mAb at 1 μg/ml 10⁸ cells /ml.

Heinrich, G., Gram, H., Kocher, H. P., Schreier, M. H., Ryffel, B., Akbar, A., ... & Janossy, G. (1989). Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions. The Journal of Immunology, 143(11), 3589-3597.

Figure 5 Half-life measurements of CHTZ In Rhesus monkeys.

In monkey El3the CHTZ half-life is 4.2 days (R = 0.992) and in monkey E14 the half-life is 5.0 days (R≈0.997).

Heinrich, G., Gram, H., Kocher, H. P., Schreier, M. H., Ryffel, B., Akbar, A., ... & Janossy, G. (1989). Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions. The Journal of Immunology, 143(11), 3589-3597.